BioWorld

Jan. 9, 2004

Opportunistic Axonyx Raises $50M Through Public Market

Months after raising $25 million in a private placement, Axonyx Inc. is at it again. But this time, Axonyx has set its sights higher, looking to bring in $50 million. (BioWorld Today) Read More

Novacea Series C Gets $35M To Push Cancer Compounds

Myogen Begins Enrollment For Ambrisentan Phase III Studies

Esperion Gets $32.2M From Settlement With Stockholder

Keryx Acquiring Three Phase II Drugs In 'Success-Based' Buyout

With 'Hybrid' Business Model, Infinity Signs Amgen To Deal

ImmunoGen Moving Forward Alone With Cancer Products

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026